Literature DB >> 31123775

Long-term Outcome of Angioplasty Using a Wingspan Stent, Post-Stent Balloon Dilation and Aggressive Restenosis Management for Intracranial Arterial Stenosis.

Seong-Cheol Park1, Su Hee Cho1, Moon-Kyu Kim1, Ji-Eun Kim2, Woo-Young Jang2, Moon-Kyu Lee2, Kwang-Deog Jo2, Seung-Hoon You3.   

Abstract

PURPOSE: To investigate the long-term outcome of stent angioplasty for symptomatic severe intracranial artery stenosis.
METHOD: In this study 95 consecutive patients with intracranial atherosclerotic stenosis (>70%) underwent stent angioplasty using Wingspan stents. The primary endpoints were stroke or death within 30 days of the procedure and subsequent stroke attributed to the stented vessel. Disabling stroke was defined as stroke with a modified Rankin scale > 3. Secondary endpoints included transient ischemic attacks, contralateral stroke, nonstroke death, and other events. Patients underwent prestent balloon dilation with or without poststent balloon dilation, close restenosis follow-up, and selective retreatment, as required. RESULT: The mean follow-up duration was 34.9 ± 23.3 months. Primary endpoint events occurred in 23% of the patients. The median infarction volume was 2.6 ml, and 11 (68%) of 16 infarctions were <5 ml in volume. Disabling stroke occurred in 3% of patients. The primary endpoint rates were 17.9% within 30 days and 2.1% from 30 days to 1 year. Secondary endpoint events occurred in 27.3% of the patients. Mean stenosis was reduced from 76.8 ± 6.1% to 7.5 ± 13.4%. Of 80 patients who underwent angiographic follow-up, 11 (14%) experienced restenosis (≥50%) and 7 (9%) exhibited restenosis-related symptoms of transient ischemic attack. The rate of symptomatic restenosis was significantly higher in patients who underwent prestent balloon dilation alone than in patients who underwent prestent and poststent balloon dilation (p = 0.016).
CONCLUSION: The postprocedural stroke rate was similar to that observed in the SAMMPRIS study. Symptomatic restenosis may be reduced by poststent dilation, close angiographic follow-up, and retreatment.

Entities:  

Keywords:  Infarction; Intracranial atherosclerosis; Ischemic attack, transient; Retreatment; Stroke

Mesh:

Year:  2019        PMID: 31123775     DOI: 10.1007/s00062-019-00793-1

Source DB:  PubMed          Journal:  Clin Neuroradiol        ISSN: 1869-1439            Impact factor:   3.649


  6 in total

1.  A standardized method for measuring intracranial arterial stenosis.

Authors:  O B Samuels; G J Joseph; M J Lynn; H A Smith; M I Chimowitz
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

2.  The use of balloon-expandable stents in the management of intracranial arterial diseases: a 5-year single-center experience.

Authors:  Iruena Moraes Kessler; Charbel Mounayer; Michel Piotin; Laurent Spelle; Jose Ricardo Vanzin; Jacques Moret
Journal:  AJNR Am J Neuroradiol       Date:  2005-10       Impact factor: 3.825

3.  Endovascular treatment of symptomatic intracranial stenosis with the Wingspan stent system and Gateway PTA balloon: a multicenter series of 60 patients with acute and midterm results.

Authors:  Vincent Costalat; Igor Lima Maldonado; Jean-François Vendrell; Carlos Riquelme; Paolo Machi; Charles Arteaga; Francis Turjman; Hubert Desal; Jacques Sedat; Alain Bonafé
Journal:  J Neurosurg       Date:  2011-07-08       Impact factor: 5.115

4.  Intracranial angioplasty without stenting for symptomatic atherosclerotic stenosis: long-term follow-up.

Authors:  Michael P Marks; Mary L Marcellus; Huy M Do; Pamela K Schraedley-Desmond; Gary K Steinberg; David C Tong; Gregory W Albers
Journal:  AJNR Am J Neuroradiol       Date:  2005-03       Impact factor: 3.825

5.  Treatment of symptomatic intracranial atherosclerotic stenosis with a normal-sized Gateway(™) balloon and Wingspan(™) stent.

Authors:  J Yu; L Wang; J P Deng; L Gao; T Zhang; Z W Zhao; G D Gao
Journal:  J Int Med Res       Date:  2010       Impact factor: 1.671

6.  Percutaneous transluminal angioplasty for intracranial atherosclerotic lesions: evolution of technique and short-term results.

Authors:  J J Connors; J C Wojak
Journal:  J Neurosurg       Date:  1999-09       Impact factor: 5.115

  6 in total
  7 in total

1.  Tandem Short-length Multi-stent Construct for Emergent Revascularization of Occlusive Long-segment Left Middle Cerebral Artery In-stent Stenosis.

Authors:  Torin W Karsonovich; Brittany R Bolt; Ajeet Gordhan
Journal:  Cureus       Date:  2020-04-15

2.  Long-term clinical and angiographic outcome from angioplasty and stenting for intracranial stenosis.

Authors:  Sang Kyu Park; Sang Hyun Suh; Kyeong Sool Jang; Dong Kyu Jang; Dong Young Jo; Yong Sam Shin
Journal:  Acta Neurochir (Wien)       Date:  2022-01-10       Impact factor: 2.216

3.  Incidence and Risk Factors of In-Stent Restenosis for Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis.

Authors:  G Peng; Y Zhang; Z Miao
Journal:  AJNR Am J Neuroradiol       Date:  2020-07-30       Impact factor: 3.825

4.  Factors affecting in-stent restenosis after angioplasty with the Enterprise stent for intracranial atherosclerotic diseases.

Authors:  Kun Zhang; Tian-Xiao Li; Zi-Liang Wang; Bu-Lang Gao; Jian-Jun Gu; Hui-Li Gao; Yong-Feng Wang; Jin-Chao Xia
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

5.  Stenting for Symptomatic Intracranial Vertebrobasilar Artery Stenosis in Northeast of China: A Single-Center Study.

Authors:  Zhongxiu Wang; Chao Wang; Chao Li; Mingchao Shi; Shouchun Wang; Yi Yang
Journal:  Front Neurol       Date:  2021-02-16       Impact factor: 4.003

6.  Sub-satisfactory recanalization of severe middle cerebral artery stenoses can significantly improve hemodynamics.

Authors:  Kun Zhang; Wei Ren; Tian-Xiao Li; Zi-Liang Wang; Bu-Lang Gao; Jin-Chao Xia; Hui-Li Gao; Yong-Feng Wang; Jian-Jun Gu
Journal:  Front Cardiovasc Med       Date:  2022-09-29

7.  A Comparison of Safety and Effectiveness Between Wingspan and Neuroform Stents in Patients With Middle Cerebral Artery Stenosis.

Authors:  Kai Zhou; Yuan Cao; Xiao-Hui He; Zhong-Ming Qiu; Shuai Liu; Zi-Li Gong; Jie Shuai; Qing-Wu Yang
Journal:  Front Neurol       Date:  2021-05-20       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.